UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Annals of oncology, 2014-09, Vol.25 (9), p.1729-1735

2014

Volltextzugriff (PDF)

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

Oncogene, 2011-07, Vol.30 (29), p.3222-3233

2011

Volltextzugriff (PDF)

Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein

Oncogene, 2016-02, Vol.35 (7), p.929-938

2016

Volltextzugriff (PDF)

Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging

Clinical radiology, 2017-01, Vol.72 (1), p.3-10

2017

Volltextzugriff (PDF)

Refinement of breast cancer classification by molecular characterization of histological special types

The Journal of pathology, 2008-10, Vol.216 (2), p.141-150

2008

Volltextzugriff (PDF)

Compromised BRCA1-PALB2 interaction is associated with breast cancer risk

Oncogene, 2017-07, Vol.36 (29), p.4161-4170

2017

Volltextzugriff (PDF)

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age

Annals of oncology, 2010-04, Vol.21 (4), p.717-722

2010

Volltextzugriff (PDF)

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

Annals of oncology, 2022-04, Vol.33 (4), p.426-433

2022

Volltextzugriff (PDF)

EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

European journal of cancer (1990), 2023-03, Vol.181, p.79-91

2023

Volltextzugriff (PDF)

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

Annals of oncology, 2019-06, Vol.30 (6), p.927-933

2019

Volltextzugriff (PDF)

ESR1 and endocrine therapy resistance: more than just mutations

Annals of oncology, 2018-04, Vol.29 (4), p.787-789

2018

Volltextzugriff (PDF)

Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x211-x218

2012

Volltextzugriff (PDF)

PG 2.03 Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa

Breast (Edinburgh), 2015-03, Vol.24, p.S4-S5

2015

Volltextzugriff (PDF)

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer

Annals of oncology, 2015-08, Vol.26 (8), p.1704-1709

2015

Volltextzugriff (PDF)

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Annals of oncology, 2018-11, Vol.29 (11), p.2268-2268

2018

Volltextzugriff (PDF)

Corrections to “Capturing intra-tumor genetic heterogeneity byde novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle”

Annals of oncology, 2018-11, Vol.29 (11), p.2268-2268

2018

Volltextzugriff (PDF)

Marked inter- and intra-patient heterogeneity of T cell infiltrates in primary high-grade serous ovarian cancer

Gynecologic oncology, 2017-06, Vol.145, p.122-122

2017

Volltextzugriff (PDF)

validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

Breast cancer research and treatment, 2010-02, Vol.120 (1), p.83-93

2010

Volltextzugriff (PDF)

575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer

European journal of cancer (1990), 2014-11, Vol.50, p.186-186

2014

Volltextzugriff (PDF)

No common denominator for breast cancer lymph node metastasis

British journal of cancer, 2005-10, Vol.93 (8), p.924-932

2005

Volltextzugriff (PDF)

Breast cancer metastasis: markers and models

Nature reviews. Cancer, 2005-08, Vol.5 (8), p.591-602

2005

Volltextzugriff (PDF)

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

British journal of cancer, 2003-04, Vol.88 (7), p.1091-1094

2003

Volltextzugriff (PDF)

Genomic landscape of adenoid cystic carcinoma of the breast

Journal of pathology and bacteriology, 2015-10, Vol.237 (2), p.179-189

2015

Volltextzugriff (PDF)

Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers

British journal of cancer, 2004-04, Vol.90 (8), p.1531-1537

2004

Volltextzugriff (PDF)

Endometrial cancers in BRCA1 or BRCA2 germline mutations carriers

Gynecologic oncology, 2019-06, Vol.153 (3), p.e8-e9

2019

Volltextzugriff (PDF)

1 – 25 von 502

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(453)
Mit Volltextzugriff
(450)

Publikationsform

Sprache

Englisch
(490)
Deutsch
(9)
Russisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein

Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging

Refinement of breast cancer classification by molecular characterization of histological special types

Compromised BRCA1-PALB2 interaction is associated with breast cancer risk

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

ESR1 and endocrine therapy resistance: more than just mutations

Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations

PG 2.03 Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Corrections to “Capturing intra-tumor genetic heterogeneity byde novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle”

Marked inter- and intra-patient heterogeneity of T cell infiltrates in primary high-grade serous ovarian cancer

validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer

No common denominator for breast cancer lymph node metastasis

Breast cancer metastasis: markers and models

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

Genomic landscape of adenoid cystic carcinoma of the breast

Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers

Endometrial cancers in BRCA1 or BRCA2 germline mutations carriers

Suchergebnisse filtern